Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis
This study aimed to explore the clinical significance of AAA+ (ATPases associated with various cellular activities) nuclear coregulator cancer-associated (ANCCA) protein expression in endometrial carcinoma (EC). Correlations of ANCCA expression with clinicopathological factors and prognosis of EC patients were analyzed. Expression of ANCCA was detected in EC from 207 patients along with corresponding normal endometrium specimens by immunohistochemistry. ANCCA immunoreactivity was overexpressed in EC cases compared with that in normal endometrium (P < 0.001). High ANCCA expression was positively correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage, histological grade, depth of myometrial invasion, lymph node metastasis, lymph vascular space involvement, and recurrence but not with age and histological type. Patients with high ANCCA expression exhibited significantly poorer overall survival (OS) and disease-free survival (DFS) than patients with low ANCCA expression (P = 0.001 and 0.002, respectively). Cox multivariate analysis showed that high ANCCA expression was an independent prognostic factor for both OS (hazard ratio (HR) = 4.954, 95 % confidence interval (CI) = 1.537–15.966; P = 0.007) and DFS of patients with EC (HR = 4.237, 95 % CI = 1.295–13.859; P = 0.017). We identified ANCCA protein expression as a novel independent poor prognostic indicator in EC.
KeywordsANCCA/ATAD2 Immunohistochemistry Endometrial carcinoma Prognosis
We express our thanks to Dr. H-T Song for the evaluation procedures.
Conflicts of interest
This work was supported by grants of the specialized Research Fund for the Doctoral Program of Higher Education (20122307120027), postdoctoral Science Foundation of Heilongjiang Province of China (LBH-Z11067), NSFC (81201613) and the Science Foundation of Heilongjiang Province (H201336). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- 1.Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: Cancer J Clin. 2009;59(4):225–49.Google Scholar
- 5.Zou JX, Duan Z, Wang J, Sokolov A, Xu J, Chen CZ, et al. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance. Mol Cancer Res : MCR. 2014;12(4):539–49.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 2010;70(22):9402–12.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Fouret R, Laffaire J, Hofman P, Beau-Faller M, Mazieres J, Validire P, et al. A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. Clin Cancer Res : Off JAm Assoc Cancer Res. 2012;18(20):5606–16.CrossRefGoogle Scholar